WallStSmart

Applied DNA Sciences, Inc. (BNBX)vsBlackstone Group Inc (BX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Blackstone Group Inc generates 739560% more annual revenue ($15.48B vs $2.09M). BX leads profitability with a 22.7% profit margin vs 0.0%. BX appears more attractively valued with a PEG of 1.21. BX earns a higher WallStSmart Score of 75/100 (B+).

BNBX

Hold

48

out of 100

Grade: D+

Growth: 5.3Profit: 2.5Value: 5.3Quality: 4.3
Piotroski: 3/9Altman Z: -130.37

BX

Strong Buy

75

out of 100

Grade: B+

Growth: 9.3Profit: 9.0Value: 5.7Quality: 3.5
Piotroski: 3/9Altman Z: 1.29

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BNBX2 strengths · Avg: 10.0/10
Price/BookValuation
0.1x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
34.3%10/10

Revenue surging 34.3% year-over-year

BX6 strengths · Avg: 9.3/10
Return on EquityProfitability
39.0%10/10

Every $100 of equity generates 39 in profit

Operating MarginProfitability
54.4%10/10

Strong operational efficiency at 54.4%

EPS GrowthGrowth
57.3%10/10

Earnings expanding 57.3% YoY

Market CapQuality
$149.90B9/10

Large-cap with strong market position

Profit MarginProfitability
22.7%9/10

Keeps 23 of every $100 in revenue as profit

Revenue GrowthGrowth
28.6%8/10

Revenue surging 28.6% year-over-year

Areas to Watch

BNBX4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$2.72M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

BX4 concerns · Avg: 3.5/10
P/E RatioValuation
28.9x4/10

Moderate valuation

Price/BookValuation
11.4x4/10

Trading at 11.4x book value

Debt/EquityHealth
1.563/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : BNBX

The strongest argument for BNBX centers on Price/Book, Revenue Growth. Revenue growth of 34.3% demonstrates continued momentum. PEG of 1.27 suggests the stock is reasonably priced for its growth.

Bull Case : BX

The strongest argument for BX centers on Return on Equity, Operating Margin, EPS Growth. Profitability is solid with margins at 22.7% and operating margin at 54.4%. Revenue growth of 28.6% demonstrates continued momentum.

Bear Case : BNBX

The primary concerns for BNBX are EPS Growth, Market Cap, Profit Margin.

Bear Case : BX

The primary concerns for BX are P/E Ratio, Price/Book, Debt/Equity. Debt-to-equity of 1.56 is elevated, increasing financial risk.

Key Dynamics to Monitor

BNBX profiles as a hypergrowth stock while BX is a growth play — different risk/reward profiles.

BX carries more volatility with a beta of 1.56 — expect wider price swings.

BNBX is growing revenue faster at 34.3% — sustainability is the question.

BX generates stronger free cash flow (1.9B), providing more financial flexibility.

Bottom Line

BX scores higher overall (75/100 vs 48/100), backed by strong 22.7% margins and 28.6% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Applied DNA Sciences, Inc.

FINANCIAL SERVICES · ASSET MANAGEMENT · USA

Applied DNA Sciences, Inc., a biotechnology company, develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) in the Americas, Europe, Asia, and internationally. The company is headquartered in Stony Brook, New York.

Blackstone Group Inc

FINANCIAL SERVICES · ASSET MANAGEMENT · USA

Blackstone Group Inc. is an alternative asset management company specializing in real estate, private equity, hedge fund solutions, credit, secondary funds of funds, public debt and equity strategies and multiple asset classes. The company is headquartered in New York, New York with additional offices across Asia, Europe and North America.

Want to dig deeper into these stocks?